{"id":"NCT04603924","sponsor":"NeuroBo Pharmaceuticals Inc.","briefTitle":"Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients","officialTitle":"A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-10-07","primaryCompletion":"2022-02-16","completion":"2022-02-16","firstPosted":"2020-10-27","resultsPosted":"2025-05-15","lastUpdate":"2025-05-15"},"enrollment":49,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Niclosamide","otherNames":["ANA001"]},{"type":"DRUG","name":"Placebo","otherNames":["Matching Placebo to ANA001"]}],"arms":[{"label":"ANA001","type":"EXPERIMENTAL"},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Study of ANA001 in Moderate and Severe COVID-19 Patients","primaryOutcome":{"measure":"Number of Subjects Experiencing TEAEs","timeFrame":"Randomization to Day 60","effectByArm":[{"arm":"ANA001","deltaMin":16,"sd":null},{"arm":"Matching Placebo","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":22},"commonTop":["Insomnia","Anxiety","Constipation","Nausea","Hypocalcaemia"]}}